Actuate Therapeutics Inc (ACTU)

Actuate Therapeutics Inc stock is traded at $0.335, with a volume of 9,350. It is up +2.45% in the last 24 hours and down -58.72% over the past month. Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.